Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice.
Trotman J, Trinh J, Kwan YL, Estell JA, Fletcher J, Archer K, Lee K, Foo K, Curnow J, Bianchi A, Wignall L, Verner E, Gasiorowski R, Siedlecka E, Cunningham I. Trotman J, et al. Among authors: cunningham i. Intern Med J. 2017 May;47(5):542-548. doi: 10.1111/imj.13302. Intern Med J. 2017. PMID: 27753208
Examination of CD302 as a potential therapeutic target for acute myeloid leukemia.
Lo TH, Abadir E, Gasiorowski RE, Kabani K, Ramesh M, Orellana D, Fromm PD, Kupresanin F, Newman E, Cunningham I, Hart DNJ, Silveira PA, Clark GJ. Lo TH, et al. Among authors: cunningham i. PLoS One. 2019 May 10;14(5):e0216368. doi: 10.1371/journal.pone.0216368. eCollection 2019. PLoS One. 2019. PMID: 31075107 Free PMC article.
Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.
McQuilten Z, Heritier S, Fox L, Fox V, Young L, Blombery P, Cunningham I, Curnow J, Higgins A, Hiwase DK, Filshie R, Firkin F, Lacaze P, Mason K, Mills AK, Pepperell D, Patil S, Stevenson W, Szer J, Waters N, Wilson K, Ting S, Wood E. McQuilten Z, et al. Among authors: cunningham i. BMJ Open. 2024 Jan 18;14(1):e076246. doi: 10.1136/bmjopen-2023-076246. BMJ Open. 2024. PMID: 38238183 Free PMC article.
A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset.
Bryant C, Fromm PD, Kupresanin F, Clark G, Lee K, Clarke C, Silveira PA, Suen H, Brown R, Newman E, Cunningham I, Ho PJ, Gibson J, Bradstock K, Joshua D, Hart DNj. Bryant C, et al. Among authors: cunningham i. Immunol Cell Biol. 2016 May;94(5):447-57. doi: 10.1038/icb.2015.116. Epub 2016 Jan 21. Immunol Cell Biol. 2016. PMID: 26791160
CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.
Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ. Li Z, et al. Among authors: cunningham i. Haematologica. 2018 Apr;103(4):655-665. doi: 10.3324/haematol.2017.178384. Epub 2018 Jan 19. Haematologica. 2018. PMID: 29351987 Free PMC article.
Distinguishing human peripheral blood CD16+ myeloid cells based on phenotypic characteristics.
Fromm PD, Silveira PA, Hsu JL, Papadimitrious MS, Lo TH, Ju X, Kupresanin F, Romano A, Hsu WH, Bryant CE, Kong B, Abadir E, Mekkawy A, M McGuire H, Groth BFS, Cunningham I, Newman E, Gibson J, Hogarth PM, Hart DNJ, Clark GJ. Fromm PD, et al. Among authors: cunningham i. J Leukoc Biol. 2020 Feb;107(2):323-339. doi: 10.1002/JLB.5A1119-362RRR. Epub 2019 Nov 21. J Leukoc Biol. 2020. PMID: 31749181
232 results